Conversely, the loss of the FGF19/FGFR4 pathway markedly boosts sorafenib-induced ROS and apoptosis, highlighting the critical role it plays in sustaining HCC cell survival and conferring resistance to sorafenib 161. Here, FGFR4 is linked to hepatocellular carcinoma.